Asian Pacific Journal of Cancer Biology,
Год журнала:
2024,
Номер
9(2), С. 257 - 261
Опубликована: Апрель 15, 2024
The
recent
coronavirus
disease
2019
outbreak
and
viral
infections
around
the
world
has
had
an
enormous
impact
on
global
health
burden,
threatening
lives
of
many
individuals,
spatially
with
underlying
like
cancerous
patients
severe
socio-economic
consequences.
Many
pharmaceutical
biotechnology
companies
have
commenced
intensive
research
different
therapeutic
strategies,
from
repurposed
antiviral
drugs
to
vaccines
monoclonal
antibodies
prevent
spread
treat
infected
patients.
Among
various
advanced
approaches
including
cell-
gene-editing-based
therapeutics
are
also
being
investigated,
initial
results
in
in-vitro
early
phase
I
studies
been
promising.
However,
further
assessments
required.
This
article
reviews
mechanisms
for
pathogenesis
of,
discusses
available
candidates
modalities
that
evaluated
used
treatment
immune
deficient
cancers
viruses
infected.
Expert Review of Neurotherapeutics,
Год журнала:
2024,
Номер
24(9), С. 879 - 895
Опубликована: Авг. 1, 2024
Introduction
High-grade
glioma
(HGG)
is
one
of
the
most
deadly
and
difficult
cancers
to
treat.
Despite
intense
research
efforts,
there
has
not
been
a
significant
breakthrough
in
treatment
outcomes
since
early
2000's.
Anti-glioma
gene
therapy
demonstrated
promise
preclinical
studies
under
investigation
numerous
clinical
trials.
International Journal of Molecular Sciences,
Год журнала:
2023,
Номер
24(13), С. 10546 - 10546
Опубликована: Июнь 23, 2023
Glioma
is
one
of
the
most
aggressive
types
primary
brain
tumor
with
a
high-grade
glioma
known
as
glioblastoma
multiforme
(GBM).
Patients
diagnosed
GBM
usually
have
an
overall
survival
rate
less
than
18
months
after
conventional
therapy.
This
bleak
prognosis
underlines
need
to
consider
new
therapeutic
interventions
for
treatment
overcome
current
limitations.
By
highlighting
different
immunotherapeutic
approaches
currently
in
preclinical
and
clinical
trials,
including
immune
checkpoint
inhibitors,
chimeric
antigen
receptors
T
cells,
natural
killer
vaccines,
combination
therapy,
this
review
aims
discuss
mechanisms,
benefits,
limitations
immunotherapy
treating
patients.
Current Cancer Drug Targets,
Год журнала:
2024,
Номер
24(9), С. 967 - 974
Опубликована: Фев. 4, 2024
Cancer
is
a
major
cause
of
death
worldwide.
Colorectal
cancer
the
second
most
common
type.
Additional
treatments
like
chemotherapy
and
radiation
therapy
may
be
recommended.
Developing
new
techniques
vital
due
to
drug
resistance
lack
targeted
therapies.
Asian Pacific Journal of Cancer Biology,
Год журнала:
2024,
Номер
9(2), С. 257 - 261
Опубликована: Апрель 15, 2024
The
recent
coronavirus
disease
2019
outbreak
and
viral
infections
around
the
world
has
had
an
enormous
impact
on
global
health
burden,
threatening
lives
of
many
individuals,
spatially
with
underlying
like
cancerous
patients
severe
socio-economic
consequences.
Many
pharmaceutical
biotechnology
companies
have
commenced
intensive
research
different
therapeutic
strategies,
from
repurposed
antiviral
drugs
to
vaccines
monoclonal
antibodies
prevent
spread
treat
infected
patients.
Among
various
advanced
approaches
including
cell-
gene-editing-based
therapeutics
are
also
being
investigated,
initial
results
in
in-vitro
early
phase
I
studies
been
promising.
However,
further
assessments
required.
This
article
reviews
mechanisms
for
pathogenesis
of,
discusses
available
candidates
modalities
that
evaluated
used
treatment
immune
deficient
cancers
viruses
infected.
